Page last updated: 2024-11-05

trioxsalen and Neoplasms

trioxsalen has been researched along with Neoplasms in 3 studies

Trioxsalen: Pigmenting photosensitizing agent obtained from several plants, mainly Psoralea corylifolia. It is administered either topically or orally in conjunction with ultraviolet light in the treatment of vitiligo.
lactone : Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring.
antipsoriatic : A drug used to treat psoriasis.
trioxsalen : 7H-Furo[3,2-g]chromen-7-one in which positions 2, 5, and 9 are substituted by methyl groups. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered orally in conjunction with UV-A for phototherapy treatment of vitiligo. After photoactivation it creates interstrand cross-links in DNA, inhibiting DNA synthesis and cell division, and can lead to cell injury; recovery from the cell injury may be followed by increased melanisation of the epidermis.

Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.

Research Excerpts

ExcerptRelevanceReference
"We performed a record linkage study of 337 male and 190 female patients with psoriasis treated with trioxsalen bath PUVA during the period 1977 to 1988 and the Finnish Cancer Registry (cancer incidence in the period 1977 to 1993)."7.69Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. ( Hannuksela, A; Hannuksela, M; Karvonen, J; Pukkala, E, 1996)
"We performed a record linkage study of 337 male and 190 female patients with psoriasis treated with trioxsalen bath PUVA during the period 1977 to 1988 and the Finnish Cancer Registry (cancer incidence in the period 1977 to 1993)."3.69Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. ( Hannuksela, A; Hannuksela, M; Karvonen, J; Pukkala, E, 1996)

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19901 (33.33)18.7374
1990's1 (33.33)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lin, R1
Elf, S1
Shan, C1
Kang, HB1
Ji, Q1
Zhou, L1
Hitosugi, T1
Zhang, L1
Zhang, S1
Seo, JH1
Xie, J1
Tucker, M1
Gu, TL1
Sudderth, J1
Jiang, L1
Mitsche, M1
DeBerardinis, RJ1
Wu, S1
Li, Y1
Mao, H1
Chen, PR1
Wang, D1
Chen, GZ1
Hurwitz, SJ1
Lonial, S1
Arellano, ML1
Khoury, HJ1
Khuri, FR1
Lee, BH1
Lei, Q1
Brat, DJ1
Ye, K1
Boggon, TJ1
He, C1
Kang, S1
Fan, J1
Chen, J1
Hannuksela, A1
Pukkala, E1
Hannuksela, M1
Karvonen, J1
Sieber, SM1
Adamson, RA1

Reviews

1 review available for trioxsalen and Neoplasms

ArticleYear
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
    Nature cell biology, 2015, Volume: 17, Issue:11

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;

2015

Other Studies

2 other studies available for trioxsalen and Neoplasms

ArticleYear
Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA.
    Journal of the American Academy of Dermatology, 1996, Volume: 35, Issue:5 Pt 1

    Topics: Adolescent; Adult; Aged; Female; Finland; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; N

1996
Letter: Selection of carriers for alkylating moieties to increase their antitumor specificity.
    Cancer treatment reports, 1976, Volume: 60, Issue:3

    Topics: Alkylating Agents; Animals; Biopharmaceutics; Chemical Phenomena; Chemistry; Humans; Methoxsalen; Ne

1976